Emoxypine

Last updated

Emoxypine
2-Ethyl-6-methyl-3-hydroxypyridine.svg
Emoxypine ball-and-stick.png
Clinical data
Trade names Mexidol
Other namesEmoxipine, Emoxypin, Epigid, 6-Methyl-2-ethyl-3-hydroxypyridine
Routes of
administration
Oral & IV
ATC code
  • none
Legal status
Legal status
  • US:Unscheduled; not FDA approved
  • RU: Rx only
Pharmacokinetic data
Elimination half-life 2-2.6 h
Identifiers
  • 2-Ethyl-6-methyl-3-hydroxypyridine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.205.098 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H11NO
Molar mass 137.182 g·mol−1
3D model (JSmol)
Melting point 170 to 172 °C (338 to 342 °F) [1]
  • CCc1c(ccc(n1)C)O

  • Oc1ccc(nc1CC)C
  • InChI=1S/C8H11NO/c1-3-7-8(10)5-4-6(2)9-7/h4-5,10H,3H2,1-2H3
  • Key:JPGDYIGSCHWQCC-UHFFFAOYSA-N
   (verify)

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties, [2] [3] but these purported properties of emoxypine have not been proven. [4] Its chemical structure resembles that of pyridoxine (a type of vitamin B6).

Contents

History

Emoxypine was first synthesized by L.D. Smirnov and K.M. Dumayev, then studied and developed in the Russian Institute of Pharmacology, Russian Academy of Medical Sciences and Russian Scientific Center of Bioactive Substances Safety. [5] Its research and use has been largely isolated to former soviet states, with little interest from other countries. [6]

Use

Emoxypine is widely used in Russia, primarily for its anti-oxidant properties claimed by the manufacturer. It purportedly exercises anxiolytic, [7] [8] anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory action.[ citation needed ] Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action. [5] Compound's iron chelating property in vitro, shows potential in the management of neurodegenerative conditions such as Alzheimer's disease (AD), as well as hematologic disorders. [6]

Mechanism of action

Emoxypine's purported mechanism of action is believed to be its antioxidant and membrane-protective effects with the following key components: [5] [9] [ medical citation needed ] Still, the antioxidant and membrane-protective effects have not been proved in reviews and meta-analysis [4] [ medical citation needed ] The purported actions of emoxypine are:

Clinical study

One non-blinded non-randomized study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR led to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy. [5] [4] Still, these studies were primary research not confirmed in reviews and meta-analysis. [11] Based on the available information, [4] it can be concluded that the effectiveness or purported pharmaceutical efficiency of emoxypine has not been confirmed through comprehensive reviews or meta-analyses. Most of the studies on emoxypine are primary research and have not been validated in systematic reviews or meta-analyses. [4]

Emoxypine is an uncontrolled substance in the United States meaning it is legal to possess without a license or prescription.

See also

Related Research Articles

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">Benzodiazepine</span> Class of depressant drugs

Benzodiazepines, colloquially known as "benzos", are a class of depressant drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. They are prescribed to treat conditions such as anxiety disorders, insomnia, and seizures. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and was made available in 1960 by Hoffmann–La Roche, which followed with the development of diazepam (Valium) three years later, in 1963. By 1977, benzodiazepines were the most prescribed medications globally; the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, decreased rates of prescription, but they remain frequently used worldwide.

Coenzyme Q<sub>10</sub> Biochemical cofactor and antioxidant

Coenzyme Q10 (CoQ10) also known as ubiquinone, is a naturally occurring biochemical cofactor (coenzyme) and an antioxidant produced by the human body. It can also be obtained from dietary sources, such as meat, fish, seed oils, vegetables, and dietary supplements. CoQ10 is found in many organisms, including animals and bacteria.

<span class="mw-page-title-main">Local anesthetic</span> Medications to reversibly block pain

A local anesthetic (LA) is a medication that causes absence of all sensation in a specific body part without loss of consciousness, providing local anesthesia, as opposed to a general anesthetic, which eliminates all sensation in the entire body and causes unconsciousness. Local anesthetics are most commonly used to eliminate pain during or after surgery. When it is used on specific nerve pathways, paralysis also can be induced.

<span class="mw-page-title-main">Beta blocker</span> Medications for abnormal heart rhythms

Beta blockers, also spelled β-blockers, are a class of medications that are predominantly used to manage abnormal heart rhythms (arrhythmia), and to protect the heart from a second heart attack after a first heart attack. They are also widely used to treat high blood pressure, although they are no longer the first choice for initial treatment of most patients.

<span class="mw-page-title-main">Pioglitazone</span> Chemical compound

Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. It may be used with metformin, a sulfonylurea, or insulin. Use is recommended together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.

<span class="mw-page-title-main">Piracetam</span> Chemical compound

Piracetam is a drug that has efficacy in cognitive disorders, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia; sources differ on its usefulness for dementia. Piracetam is sold as a medication in many European countries. Sale of piracetam is not illegal in the United States, although it is not regulated nor approved by the FDA, so it is legally sold for research use only.

<span class="mw-page-title-main">Amphotericin B</span> Antifungal and antiparasitaric chemical compound

Amphotericin B is an antifungal medication used for serious fungal infections and leishmaniasis. The fungal infections it is used to treat include mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis. For certain infections it is given with flucytosine. It is typically given intravenously.

<span class="mw-page-title-main">Metoprolol</span> Medication of the selective β1 receptor blocker type

Metoprolol, sold under the brand name Lopressor among others, is a medication used to treat angina and a number of conditions involving an abnormally fast heart rate. It is also used to prevent further heart problems after myocardial infarction and to prevent headaches in those with migraines. It is a selectiveβ1 receptor blocker medication. It is taken by mouth or is given intravenously.

The vitamin E family comprises four tocotrienols and four tocopherols. The critical chemical structural difference between tocotrienols and tocopherols is that tocotrienols have unsaturated isoprenoid side chains with three carbon-carbon double bonds versus saturated side chains for tocopherols.

<span class="mw-page-title-main">Traction (orthopedics)</span> Process for straightening broken bones

Traction is a set of mechanisms for straightening broken bones or relieving pressure on the spine and skeletal system. There are two types of traction: skin traction and skeletal traction. They are used in orthopedic medicine.

<span class="mw-page-title-main">Lercanidipine</span> Antihypertensive drug of the calcium channel blocker class

Lercanidipine is an antihypertensive drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.

<span class="mw-page-title-main">Melperone</span> Antipsychotic drug

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

<span class="mw-page-title-main">Radiculopathy</span> Medical condition

Radiculopathy, also commonly referred to as pinched nerve, refers to a set of conditions in which one or more nerves are affected and do not work properly. Radiculopathy can result in pain, weakness, altered sensation (paresthesia) or difficulty controlling specific muscles. Pinched nerves arise when surrounding bone or tissue, such as cartilage, muscles or tendons, put pressure on the nerve and disrupt its function.

<span class="mw-page-title-main">Ampelopsin</span> Chemical compound

Ampelopsin, also known as dihydromyricetin and DHM, when purported as an effective ingredient in supplements and other tonics, is a flavanonol, a type of flavonoid. It is extracted from the Japanese raisin tree and found in Ampelopsis species japonica, megalophylla, and grossedentata; Cercidiphyllum japonicum; Hovenia dulcis; Rhododendron cinnabarinum; some Pinus species; and some Cedrus species, as well as in Salix sachalinensis.

<span class="mw-page-title-main">Nooglutyl</span> Chemical compound

Nooglutyl is a nootropic agent that was studied at the Research Institute of Pharmacology, Russian Academy of Medical Sciences as a potential treatment for amnesia.

<span class="mw-page-title-main">Saroglitazar</span> Chemical compound

Saroglitazar is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.

<span class="mw-page-title-main">Discovery and development of beta-blockers</span>

β adrenergic receptor antagonists were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. In the 1950s, dichloroisoproterenol (DCI) was discovered to be a β-antagonist that blocked the effects of sympathomimetic amines on bronchodilation, uterine relaxation and heart stimulation. Although DCI had no clinical utility, a change in the compound did provide a clinical candidate, pronethalol, which was introduced in 1962.

Zinc L-carnosine, often simply called zinc carnosine, and also known as polaprezinc, is a mucosal protective chelate compound of zinc and L-carnosine invented by Hamari Chemicals, Ltd. It is a quadridentate 1:1 complex of a polymeric nature. Although it contains 23% zinc and 77% L-carnosine by mass, zinc carnosine is a molecule and not a mixture of zinc and L-carnosine.

Actoprotectors or synthetic adaptogens are compounds that enhance an organism's resilience to physical stress without increasing heat output. Actoprotectors are distinct from other performance-enhancing substances in that they increase physical and psychological resilience via non-exhaustive action. The term "actoprotector" is used to describe synthetic and isolated compounds possessing adaptogenic properties. By contrast, the term "adaptogen" is most often use to describe a natural herb as a whole, which can contain hundreds if not thousands of biologically active components.

References

  1. Gruber W (1953). "Synthesis of 3-Hydroxy-2-alkylpyridines". Canadian Journal of Chemistry. 31 (6): 564–568. doi: 10.1139/v53-079 .
  2. "mexidol.ru, Pharmasoft Website". Archived from the original on 2011-04-10. Retrieved 2011-04-27.
  3. Yakovlev IY (2013). "Механізми актопротекторної дії похідних янтарної кислоти" [Mechanisms of actoprotective action of succinic acid's derivatives]. Лікарська справа (in Ukrainian) (3): 78–85. PMID   25016753.
  4. 1 2 3 4 5 Likhacheva EB, Sholomov II (2006). "[Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy]". Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 106 (10): 52–7. PMID   17117675.
  5. 1 2 3 4 5 Voronina TA. "ANTIOXIDANT MEXIDOL. The main neuropsychotropic effects and the mechanism of action". Institute of Pharmacology. Moscow, Russia: Russian Academy of Medical Sciences. Archived from the original on 2013-11-05.
  6. 1 2 Gupta DS, Bagwe Parab S, Kaur G (1 January 2022). "Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applications". Current Research in Pharmacology and Drug Discovery. 3: 100121. doi:10.1016/j.crphar.2022.100121. PMC   9389226 . PMID   35992374.
  7. Volchegorskii IA, Miroshnichenko IY, Rassokhina LM, Faizullin RM, Malkin MP, Pryakhina KE, et al. (April 2015). "Comparative analysis of the anxiolytic effects of 3-hydroxypyridine and succinic acid derivatives". Bulletin of Experimental Biology and Medicine. 158 (6): 756–61. doi:10.1007/s10517-015-2855-3. PMID   25894772. S2CID   6052275.
  8. Rumyantseva SA, Fedin AI, Sokhova ON (October 2012). "Antioxidant Treatment of Ischemic Brain Lesions". Neuroscience and Behavioral Physiology. 42 (8): 842–845. doi:10.1007/s11055-012-9646-3. S2CID   39971165.
  9. Dumayev KM, Voronina TA, Smirnov LD (1995). Antioxidants in the prophylaxis and therapy of CNS pathologies (Report). Moscow.[ page needed ]
  10. Kucherianu VG (January 2001). "[Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model]". Eksperimental'naia i Klinicheskaia Farmakologiia. 64 (1): 22–5. PMID   11544797.
  11. Da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. (2021). "Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: Network meta-analysis". BMJ (Clinical Research Ed.). 375: n2321. doi:10.1136/bmj.n2321. PMC   8506236 . PMID   34642179.